Table I.
Number and characteristics of the subjects in the IBD study [16].
| Ha | UCb | CDc | UC-Ud | CD-Ue | |
|---|---|---|---|---|---|
| Subjects | 20 | 37 | 7 | 44 | 19 |
| Age, median years (range) | 45 (19–71) | 38 (19–72) | 31 (20–41) | 45 (21–71) | 39 (20–61) |
| Female/Male | 9/11 | 22/15 | 2/5 | 24/20 | 6/13 |
| Duration of disease, median years (range) | NAf | 9 (0–40) | 7 (1–12) | 13 (0–40) | 6 (0–28) |
| 5-ASAg/sulphasalzine (%) | 0 | 23 (62) | 2 (29) | 27 (61) | 6 (32) |
| Systemic corticosteroids (%) | 0 | 9 (26) | 2 (29) | 4 (9) | 8 (42) |
aHealthy, bUlcerative colitis, cCrohn’s disease, dUn-inflamed UC, eUn-inflamed CD, fNot applicable, g5-aminosalisylic acid.